Equillium Announces Poster Presentation at the 50th Anniversary La Jolla Immunology ConferenceGlobeNewsWire · Oct 6, 2026
Equillium Receives Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of EQ504GlobeNewsWire · Oct 5, 2026
Equillium Announces Poster Presentations at the 7th International AHR ConferenceGlobeNewsWire · Sep 29, 2026
Equillium Eyes Q4 Phase I Start for Ulcerative Colitis Drug EQ504Defense World · Sep 28, 2026
Equillium Eyes Q4 Phase I Start for Ulcerative Colitis Drug EQ504MarketBeat · Sep 27, 2026
Equillium to Participate in Stifel's 2026 Virtual Immunology and Inflammation ForumGlobeNewsWire · Sep 16, 2026Equillium, Inc. is a clinical-stage biopharmaceutical company focused on developing and bringing to market products designed to address severe autoimmune and inflammatory (immuno-inflammatory) disorders where current treatment options are insufficient. The company's primary drug candidate is itolizumab (EQ001), a monoclonal antibody in clinical development that targets the novel CD6 immune checkpoint receptor. Itolizumab is currently in Phase III trials for acute graft-versus-host disease, has completed Phase Ib studies for asthma, and is also undergoing Phase Ib trials for lupus nephritis.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 13, 2026 | -$0.05 | -$0.04 | Beat |
| May 13, 2026 | -$0.04 | -$0.06 | Miss |
| Mar 25, 2026 | -$0.07 | -$0.04 | Beat |
| Nov 13, 2025 | -$0.14 | -$0.06 | Beat |
| Aug 14, 2025 | -$0.14 | -$0.16 | Miss |
| May 14, 2025 | -$0.23 | -$0.24 | Miss |